2. Signaling Pathways
  3. Cytoskeleton
  4. Annexin A

Annexin A

AnxA

Annexin A (AnxA) family, the well-known Ca2+ phospholipid-binding protein, have many functions in regulating inflammation-related enzymes and cell signaling transduction, thus influencing cell adhesion, migration, differentiation, proliferation and apoptosis.

Annexin A Isoform Specific Products:

Annexin A Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-141644
    PY-60
    		Activator 99.42%
    PY-60 is a robust and specific activator of YAP transcriptional activity that targets annexin A2 (ANXA2) with a Kd of 1.4 µM. PY-60 directly binds to ANXA2 and antagonizes its normal cellular function of repressing YAP activity.
    PY-60
  • HY-P1098
    Ac2-26
    		99.43%
    Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model.
    Ac2-26
  • HY-101200
    Linsidomine hydrochloride
    		Inhibitor 99.97%
    Linsidomine hydrochloride (SIN-1 chloride) is a spontaneous ROS/RNS generator and peroxynitrite donor. Linsidomine hydrochloride is a vasodilator and platelet aggregation inhibitor. Linsidomine hydrochloride induces oxidative stress-induced chondrocyte apoptosis and necrosis. Linsidomine hydrochloride inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of Linsidomine hydrochloride shows protective effects on Zn2+ treated nerve cells.
    Linsidomine hydrochloride
  • HY-136465
    A2ti-1
    		Inhibitor 99.78%
    A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection.
    A2ti-1
  • HY-P1098A
    Ac2-26 TFA
    		98.09%
    Ac2-26 TFA is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model.
    Ac2-26 TFA
  • HY-P992100
    Amesotatug
    		Inhibitor
    Amesotatug is a humanized monoclonal antibody and ANXA1 binder. Amesotatug binds to Homo sapiens ANXA1 and exhibits antineoplastic activity. Amesotatug can be used for the research of cancer.
    Amesotatug
  • HY-16254
    Hydrocortamate hydrochloride
    		Inhibitor
    Hydrocortamate hydrochloride is a broad-spectrum immunosuppressant. Hydrocortamate hydrochloride has been identified as a potential inhibitor of T cell proliferation in ischemia-reperfusion injury (IRI), specifically targeting the ANXA1 gene. Hydrocortamate hydrochloride can be used in inflammation research.
    Hydrocortamate hydrochloride
  • HY-P2333
    LCKLSL
    		Inhibitor 99.26%
    LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles.
    LCKLSL
  • HY-P2333A
    LCKLSL hydrochloride
    		Inhibitor 98.05%
    LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles.
    LCKLSL hydrochloride
  • HY-136466
    A2ti-2
    		Inhibitor 99.80%
    A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection.
    A2ti-2
  • HY-125355
    SEC
    		Inhibitor 98.26%
    SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation.
    SEC
  • HY-P10412
    A11
    		98.49%
    A11 (ANXA1-derived 11 amino acid-long peptide) is a ANXA1-EphA2 interaction-blocking peptide. A11 reduces ANXA1 bound to EphA2 and increases Cbl (the E3 ubiquitin ligase of EphA2) bound to EphA2. A11 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells. A11 inhibits angiogenesis. A11 can be used in studies related to nasopharyngeal carcinoma.
    A11
  • HY-115635
    ABO hydrochloride
    		Modulator 98.7%
    ABO hydrochloride is a potent modulator of ANXA7 as ABO binds to Thr286 of ANXA7 and inhibits its phosphorylation. ABO promotes autophagy via elevation of ANXA7 and triggering ANXA7 subcellular redistribution.
    ABO hydrochloride
  • HY-169212
    I194496
    		Inhibitor 98.52%
    I194496 is a potent cystathionine γ-lyase (CSE) inhibitor, with an IC50 of 0.79 mM. I194496 can inhibit the growth of human TNBC cells via the dual targeting PI3K/Akt and Ras/Raf/ERK pathway and suppress the metastasis of human TNBC cells via down-regulating Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.
    I194496
  • HY-159621
    Endosidine 5
    		99.80%
    Endosidine 5 (ES5) inhibits EPS (extracellular polymeric substance) secretion and cell wall expansion. Endosidine 5 alters secretion of ECM (extracellular matrix) material in Penium margaritaceum by affecting the Golgi apparatus. Endosidine 5 interferes with recycling endosomes through Annexin A6, thereby promoting the release and expression of mRNA into the cytoplasm.
    Endosidine 5
  • HY-RS00759
    ANXA11 Human Pre-designed siRNA Set A

    ANXA11 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    ANXA11 siRNA-1: 5 nmol (HPLC)

    ANXA11 siRNA-2: 5 nmol (HPLC)

    ANXA11 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)
    ANXA11 Human Pre-designed siRNA Set A
  • HY-106752
    CI-936
    		Agonist
    CI-936 (MRS-3310) is an orally active A2 agonist with 25 nM affinity. CI-936 produces potent and selective effects in preclinical tests predictive of antipsychotic efficacy. CI-936 inhibits exploratory activity in mice.
    CI-936
  • HY-168951
    (R)-SL18
    		Degrader
    (R)-SL18 is a degrader of ANXA3 and can degrade ANXA3 protein through the ubiquitination pathway. (R)-SL18 inhibits the proliferation, migration, invasion, and colony formation of breast cancer cells and induces apoptosis. (R)-SL18 can be used in the research of triple-negative breast cancer.
    (R)-SL18
  • HY-176548
    PY-PAP
    		Ligand
    PY-PAP is a photoactivatable affinity probe and a derivative of PY-60 (HY-141644). PY-PAP retains the cellular function of activating YAP transcriptional activity. In 293A cells, PY-PAP can label cathepsin D (CTSD) and annexin A2 (ANXA2) through ultraviolet crosslinking and click reactions. PY-PAP plays a key role in identifying ANXA2 as the specific target of PY-60.
    PY-PAP
  • HY-P10412A
    A11 acetate
    		98.48%
    A11 (ANXA1-derived 11 amino acid-long peptide) acetate is a ANXA1-EphA2 interaction-blocking peptide. A11 acetate reduces ANXA1 bound to EphA2 and increases Cbl (the E3 ubiquitin ligase of EphA2) bound to EphA2. A11 acetate inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells. A11 acetate inhibits angiogenesis. A11 acetate can be used in studies related to nasopharyngeal carcinoma.
    A11 acetate
Annexin A Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.